Printer Friendly

BIGMAR GETS BRAZILIAN APPROVAL TO MARKET FLUOROURACIL.

Bigmar Inc. (Nasdaq:BGMR), Johnstown, Ohio, has received approval from Brazil's Agencia Nacional de Vigilancia Sanitaria (ANVS) to market 5-fluorouracil in Brazil.

A potent anticancer agent, 5-fluorouracil is used in combination with other drugs to treat ovarian and breast cancer. The ANVS action marks the first oncological product approval received by Bigmar in Brazil.

"We intend to market 5-fluorouracil under the Bigmar label," said John G. Tramontana, chairman and chief executive officer. "We anticipate receiving ANVS approvals for additional oncology products during 2000.

"The anticancer market in Brazil is growing at a substantial rate," Tramontana added. "We hope to capture a material share of the generic business in the near term."

Bigmar is a manufacturer of generic pharmaceutical oncology products and intravenous infusion solutions, which it manufactures at its state-of-the-art facilities in Switzerland. The company markets its products through partnerships of pharmaceutical distributors in Europe and the United States and focuses on off-patent oncological pharmaceuticals. For more information, visit the company's Web site, www.bgmr.com or call 740/966-5800.
COPYRIGHT 2000 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Comment:BIGMAR GETS BRAZILIAN APPROVAL TO MARKET FLUOROURACIL.
Publication:Worldwide Biotech
Article Type:Brief Article
Geographic Code:1USA
Date:Jul 1, 2000
Words:170
Previous Article:BABIES TO BE SCREENED FOR DIABETES RISK GENES IN SWEDEN.
Next Article:NATIONAL RESEARCH COUNCIL OF CANADA ACCEPTS AUTOMATED LAB.
Topics:


Related Articles
Therapy improves rectal cancer outlook.
SWISS IKS APPROVES FORMULATION OF METRONIDAZOLE IN IV BAGS.
The Spectacle of the Races: Scientists, Institutions, and the Race Question in Brazil, 1870-1930.
FDA approves Eloxatin for colorectal cancer.
Editorial.
Hallucinogenic tea: a constitutional right?

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters